CURRICULUM VITAE

ARISTEIDIS BOUKOURIS, MD, PhD

ASSISTANT PROFESSOR OF MEDICAL ONCOLOGY
UNIVERSITY OF CRETE MEDICAL SCHOOL

Last update: November 1, 2026

Contents

Personal Information ____ 3

Studies ____ 3

Academic Distinctions ____ 4

Scholarships ____ 5

Research Experience ____ 6

Clinical Experience ____ 7

Teaching Experience ____ 8

Peer-reviewed publications ____ 9

Scientific publication memo ____ 12

Books and chapters ____ 13

Scientific publication reviewer ____ 14

Invited talks ____ 14

Presentations in scientific conferences ____ 15

Participation in educational conferences ____ 17

Membership in scientific societies ____ 18

Certifications ____ 18

Foreign languages ____ 18

Voluntary work ____ 18

Personal Information

First Name: Aristeidis

Surname: Boukouris

Father's name: Evangelos

Mother's name: Konstantina

Marital Status: Married

Nationality: Greek

Address: Stravonos 43, Heraklion, 71305 Crete, Greece

Phone number: 6945-282808

E-mail: arisbouk@uoc.gr

Studies

1. PhD, University of Alberta, Edmonton, Canada

Topic: The impact of metabolic stress on critical cell fate decisions in cancer

Title: "*A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer*"

Finish: 19/11/2021. Start: 01/09/2014

Supervisor: Evangelos Michelakis, MD

2. PhD, Hannover Medical School, Hannover, Germany

Topic: The role of the PI3K/mTOR pathway in hepatocellular carcinoma

Title: "*Molecular mechanisms of PI3K/mTOR-targeted therapies in hepatocellular cancer*"

Finish: 23/04/2015. Start: 20/01/2012

Supervisor: Arndt Vogel, MD, PhD

3. MD, Medical Diploma, Medical School, National and Kapodistrian University of Athens (NKUA)

Performance: "Magna cum laude"

Finish: 08/2011. Start: 09/2005

Academic distinctions

1. **3rd Best Oral Presentation Award – 26th Panhellenic Congress of Internal Medicine, Athens (2023)**

   Title: "The significant contribution of internists to the management of hospitalized patients primarily treated by other specialties"

2. **Best Oral Presentation Award – University of Alberta Department of Medicine Annual Research Day (2018)**

   All resident physicians, graduate and postdoctoral students of the University of Alberta, Department of Medicine participated in the competition

3. **University of Alberta Faculty of Medicine and Dentistry Dean's Doctoral Award (2018)**

   Awarded to PhD students with outstanding academic performance. Value: $12,500 annually. Duration: up to 3 years

4. **University of Alberta Faculty of Medicine and Dentistry 75th Anniversary Award (2017)**

   Awarded to PhD students with outstanding academic performance. Value: $7,000 annually

5. **Graduation with the 3rd best performance (top 1%)** among all graduates of the Medical School of the National and Kapodistrian University of Athens (2011)

6. **State Scholarship Foundation (IKY) Award for outstanding academic performance (top 1%)** among all students. Academic years: 2006-2007, 2007-2008 and 2008-2009

7. **Eurobank Group Award for graduating 1st** among all 3rd grade students of Nafplion 2nd High School

Scholarships

1. **Research Fellowship from the Bodossaki Foundation (2014)**

   Personal funding following evaluation of the research proposal for my second PhD thesis (University of Alberta). Value: ~ €9,000 annually. Duration: 2 years

2. **Research Fellowship from German Liver Cancer SFB / TRR77 – From Molecular Pathogenesis to Targeted Therapies (2012)**

   Personal funding following evaluation of research progress to support my first PhD thesis (Hannover Medical School). Value: ~ €1,000 monthly. Duration: 9 months

3. **Research Fellowship from the German Academic Exchange Service (DAAD) (2012)**

   Personal funding following evaluation of research progress to support my first PhD thesis (Hannover Medical School). Value: ~ €6,300 annually. Duration: 1 year

4. **Research Fellowship from Onassis Foundation (2012)**

   Personal funding following evaluation of the research proposal for my first PhD thesis (Hannover Medical School). Value: €12,000 annually. Duration: 2 years

5. **Undergraduate Scholarship from Latsis Foundation (years: 2007, 2008, 2009, 2010)**

   Scholarship for undergraduate students with excellent academic performance (top 1% of each academic year)

Research Experience

My research activity has so far focused on two main subjects within the broader field of cancer cell metabolism:

A. The role of the PI3K/mTOR signaling pathway in hepatocellular carcinoma, and the study of predictive molecular factors for the cellular response to inhibitors of this pathway. Our results showed that PI3K/mTOR inhibitors reduce the proliferative capacity of cells through the reduction of mitochondrial metabolism.

B. The role of metabolic stress in regulating important cellular decisions (cell fate) such as metastasis. My research revealed the role of a previously poorly studied cytoskeletal protein, CRMP2A, in regulating the stemness and metastatic ability of cells. Under poor energy supply (hypoxia, hypoglycemia, mitochondrial stress, etc.), increase in non-phosphorylated CRMP2A levels inhibits the energy-demanding process of metastasis through microtubule stabilization. On the contrary, loss of this protein (both phosphorylated and non-phosphorylated forms) favors the phenotypic conversion of cells into mesenchymal-like (epithelial-to-mesenchymal transition, EMT) and confers stem cell properties to cancer cells, including chemotherapy and apoptosis resistance.

1. (Salaried position) University of Alberta, Edmonton, Canada 09/2014 – 11/2021

Doctoral student funded partially (2014-2016) or fully (2016-2021)
from the University of Alberta

2. Hannover Medical School, Hannover, Germany 01/2012 – 04/2015

Doctoral student

Clinical Experience

1. **Resident in Medical Oncology – University General Hospital of Heraklion (PaGNI)** — **08/2023 – Present**

2. **Resident in Internal Medicine – Hellenic Red Cross Hospital (Korgialeneio-Benakeio)** — **04/2021 – 07/2023**

3. **Clinical Observer in Internal Medicine – University of Alberta Hospital, Edmonton, Canada** — **07/2019**
   Unpaid clinical observer at the University of Alberta Hospital, Department of Internal Medicine. Supervisor: Dr. Peter Hwang

4. **Clinical Observer in Gastroenterology and Hepatology – Charité Campus Virchow Klinikum, Berlin, Germany** — **08/2011**
   Unpaid clinical observer, Department of Gastroenterology and Hepatology, Charité Campus Virchow Klinikum. Supervisor: Prof. Dr. Daniel Baumgart

Teaching Experience

Postgraduate Programs – University of Crete Medical School

- **Director of the postgraduate program "Oncology: From tumorigenesis to treatment"**. Academic year **2026-2027**
- **Oncology: From tumorigenesis to treatment**. Subjects taught: "Soft tissue and bone sarcomas. CNS tumors. Clinical presentation – Staging" (academic year: **2024-2025)** and "The Use of NGS Sequencing in Molecular Diagnosis and Treatment of Cancer" (academic years: **2024-2025**, **2025-2026** and **2026-2027**).
- **Hematology – Oncology of Children and Adolescents**. Subject taught: "Epidemiology, clinical presentation, diagnosis and therapeutic principles for tumors in adolescents and young adults". Academic year: **2024-2025**
- **Biomedical Engineering**. Subject taught: "Novel therapeutic approaches in cancer treatment". Academic years: **2024-2025** and **2025-2026**

Postgraduate Program – University of Alberta, Canada

- **Translational Medicine**. Subjects taught: "Cardiomyopathies: a genetic approach" (MED602) and "How to obtain major grant funding" (MED604). Academic year: **2015-2016**

Undergraduate Programs – University of Crete Medical School

- **Propaedeutic Pathology** (6^{th} semester) – Responsible (together with another faculty member) for the clinical training of students in the Medical Oncology Clinic. Academic years: **2024-2025** and **2025-2026**. Duration of training per year: 3 months. Total teaching hours: 106
- **Internal Medicine A** (core 4^{th} year course). Subject taught "Oncologic emergencies". Academic years: **2024-2025, 2025-2026** and **2026-2027**
- **International Program in Internal Medicine**. Subjects taught: "Cancer Markers", Lung Cancer", "Breast Cancer" και "Testicular Cancer". Academic year: **2026-2027**
- **Therapeutic Strategy of Neoplastic Diseases** (6^{th} year elective course). Subjects taught: "Basic principles of systemic cancer treatment" (academic years: **2024-2025**, **2025-2026** and

2026-2027) and "The Use of NGS Sequencing in Molecular Diagnosis and Treatment of Cancer" (academic years: **2025-2026** and **2026-2027**).

- **Basic principles and mechanisms of tumorigenesis** (3rd year elective course). Subjects taught: "Biomarkers based on oncogenic mechanisms" (academic year: **2026-2027**) and "Caner Metabolism" (academic years: **2025-2026** and **2026-2027**)
- **Palliative care in cancer patients** (5th year elective course). Subjects taught: "Management of most common symptoms and side effects of treatment: mucositis, neurotoxicity, myelotoxicity" (academic year: **2025-2026**)
- **Grand Rounds –** 5th year medical students. Supervising professor in case presentation (November 2026)

Peer-reviewed publications (PubMed and Scopus)

1. Mortoglou M, Papadaki C, **Boukouris AE**, Michaelidou K, Vorrias E, Kamaratou M, Koronakis G, Lagoudaki E, Koutsopoulos A, Mavroudis D, Agelaki S. "Evaluation of the diagnostic and prognostic potential, and correlation with the tumor immune microenvironment of a 6-miRNA signature associated with platinum sensitivity in patients with early-stage non-small cell lung cancer". *Cancers (Basel).* 2026 In Press
2. Papadaki C, Mortoglou M, **Boukouris AE**, Gourlia K, Markaki M, Lagoudaki E, Koutsopoulos A, Tsamardinos I, Mavroudis D, Agelaki S. "MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer". *Cancers (Basel).* 2025 Jul 29;17(15):2504
3. Saleme B, Tejay S, Dembele P, Farraj RA, Zhang Y, Liu Y, **Boukouris AE**, Zervopoulos S, Haromy A, Zhao YY, Braun S, Saleme W, Sun X, Fahlman R, Glover M, Kinnaird A, Sutendra G. Michelakis ED. "Hyperacute response proteins synthesized on γ-tubulin-FTO-MARK4 translation microdomains regulate cancer's acute stress response". *Cell Rep.* 2025 Jul 22;44(7):115871
4. **Boukouris AE**, Michaelidou K, Joose SA, Charpidou A, Mavroudis D, Syrigos KN, Agelaki S. "A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer". *NPJ Precis Oncol.* 2025 Jun 13;9(1):178

5. Ziogas DC, Theocharopoulos C, Aravantinou K, **Boukouris AE**, Stefanou D, Anastasopoulou A, Lialios PP, Lyrarakis G, Gogas H. "Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results". *Crit Rev Oncol Hematol.* 2025 Apr;208:104635

6. **Boukouris AE**, Kokkinakis I, Drakos E, Sfakianaki M, Tzardi M, Mavroudis D, Souglakos J. "Case Report: A rare case of diffusely metastatic BRAF V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid gland". Research Topic: Mutational Landscape of Signaling Pathways Involved in Late- and Young-Onset Colorectal Cancer Progression. *Front Oncol.* 2025 Jan 28;15:1512000

7. Michelakis I, **Boukouris AE**, Komodromou A, Foteinou S, Dafni M. "Prognosis of hospitalized patients during different pandemic waves in Greece: Omicron innocent until proven guilty?" *Eur J Intern Med.* 2024 Mar;121:139-142

8. Maayah ZH, Ferdaoussi M, **Boukouris AE**, Takahara S, Das SK, Mackey JR, Pituskin E, Sutendra G, Paterson DI, Dyck JRB. "Endothelin Receptor Blocker Reverses Breast Cancer-induced Cardiac Remodeling". *JACC CardioOncol.* 2023 May 2;5(5):686-700

9. **Boukouris AE**, Michelakis I, Metaxas D, Karapati G, Kanellis G, Lioni A, Tzavara V. "Case Report: The devil was hidden in the mastocytes - an unusually fulminant case of indolent systemic mastocytosis in a 45-year-old patient, missed for almost 20 years". *Front Immunol.* 2023 Feb 10;14:1134587

10. Michalak M, Groenendyk J, Stoletov K, Paskevicius T, Li W, Dai N, Busaan E, Ng HH, **Boukouris AE**, Saleme B, Haromy A, Cui K, Hu M, Yan Y, Zhang R, Michelakis ED, Chen X-Z, Lewis J, Tang J, Agellon LB. "Loss of the fructose transporter SLC2A5 inhibits cancer cell migration". *Front Cell Dev Biol.* 2022 Sep 30;10:896297

11. **Boukouris AE**, Theochari M, Stefanou D, Papalampros A, Felekouras E, Gogas H, Ziogas DC. "Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update". *Crit Rev Oncol Hematol.* 2022 May;173:103663

12. **Boukouris AE**, Zhang Y, Saleme B, Kinnaird A, Zhao YY, Liu Y, Zervopoulos SD, Das SK, Mittal RD, Haromy A, Lorenzana Carrillo MA, Krysler AR, Cromwell CR, Hubbard BP, Sutendra G, Michelakis ED. "A reversible metabolic stress-sensitive regulation of

CRMP2A orchestrates cytoskeletal, metabolic remodeling and EMT, increasing metastatic potential in cancer". *Cell Rep.* 2022 Mar 15;38(11):110511

13. Zervopoulos SD, **Boukouris AE**, Saleme B, Haromy A, Tejay S, Sutendra G, Michelakis ED. An MFN2-driven mitochondria-to-nucleus tethering, allows a non-canonical pathway for the nuclear entrance of the mitochondrial pyruvate dehydrogenase complex. *Mol Cell.* 2022 Mar 3;82(5):1066-1077.e7

14. Zhang Y, Zervopoulos SD, **Boukouris AE**, Saleme B, Webster L, Liu Y, Haromy A, Tabatabaei Dakhili SA, Ussher JR, Sutendra G, Michelakis ED. "SNPs for Genes Encoding the Mitochondrial Proteins Sirtuin3 and Uncoupling Protein 2 Are Associated With Disease Severity, Type 2 Diabetes, and Outcomes in Patients With Pulmonary Arterial Hypertension and This Is Recapitulated in a New Mouse Model Lacking Both Genes". *J Am Heart Assoc.* 2021 Dec 7;10(23):e020451

15. Kinnaird A*, **Boukouris AE***, Saleme B, Dromparis P, Zervopoulos SD, Gurtu V, Sutendra G, Michelakis ED. "Interaction with p53 explains a pro-proliferative function for VHL in cancer". *J Mol Med (Berl).* 2020 Sep;98(9):1269-1278. *Authors contributed equally

16. Saleme B, Das SK, Zhang Y, **Boukouris AE**, Lorenzana Carrillo MA, Jovel J, Wagg CS, Lopaschuk GD, Michelakis ED, Sutendra G. "A p53-mediated repression of the PGC1α and APLNR signaling pathways limit fatty acid oxidation energetics: implications for cardio-oncology". *J Am Heart Assoc.* 2020 Aug 4;9(15):e017247

17. Saleme B, Gurtu V, Zhang Y, Kinnaird A, **Boukouris AE**, Gopal K, Ussher JR, Sutendra G. "Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity". *Sci Transl Med.* 2019 Feb 6;11(478):eaau8866

18. Michelakis ED, Gurtu V, Webster L, Barnes G, Watson G, Howard L, Cupitt J, Paterson I, Thompson RB, Chow K, O'Regan DP, Zhao L, Wharton J, Kiely DG, Kinnaird A, **Boukouris AE**, White C, Nagendran J, Freed DH, Wort SJ, Gibbs JSR, Wilkins MR. "Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients". *Sci Transl Med.* 2017 Oct 25;9(413):eaao4583

19. **Boukouris AE**[*], Zervopoulos SD[*], Michelakis ED. "Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription". *Trends Biochem Sci.* 2016 Aug; 41(8):712-30. [*]Authors contributed equally

20. Buitrago-Molina LE, Marhenke S, Longerich T, Sharma AD, **Boukouris AE**, Geffers R, Guigas B, Manns MP, Vogel A. "The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis". *Hepatology* 2013 Sep; 58(3):1143-52

21. Kirstein MM[*], **Boukouris AE**[*], Pothiraju D[*], Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A. "Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma". *Liver Int.* 2013 May; 33(5):780-93. [*]Authors contributed equally

Scientific Publication Memo

Total publications: 21

Publications as 1st/2nd author: 10

Publications as 3rd author: 4

Types of publication

Original Research Papers: 15

Review Papers: 4

Case Reports: 2

Impact of scientific work

Citations (Google Scholar: **1,332**, Scopus: **1,004**)

External citations: 1,000 (Scopus)

h-index: **12 (Google Scholar)**

i10-index: **14**

Publications per journal

Scientific Journal (in order of descending Impact Factor)	No. of publications	Impact Factor (JCR 2026)	Total Impact Factor
Hepatology	1	18.0	18.0
Molecular Cell	1	16.0	16.0
Science Translational Medicine	2	15.6	31.2
JACC: CardioOncology	1	15.5	15.5
Trends in Biochemical Sciences	1	14.4	14.4
Npj Precision Oncology	1	9.9	9.9
European Journal of Internal Medicine	1	8.1	8.1
Cell Reports	2	7.7	15.4
Frontiers in Immunology	1	7.0	7.0
Critical Reviews in Oncology Hematology	2	6.2	12.4
Liver International	1	6.2	6.2
Journal of the American Heart Association	2	6.0	12.0
Frontiers in Cell and Developmental Biology	1	5.3	5.3
Journal of Molecular Medicine	1	5.0	5.0
Cancers (Basel)	2	4.8	9.6
Frontiers in Oncology	1	3.4	3.4
Total	**21**	-	-
	Average IF	-	**9.01**

Books and Chapters

Participation in the translation of the ESMO Patient Guides for non-small cell lung cancer (NSCLC) on behalf of the Hellenic Group of Young Oncologists (HeGYO), 2022

Scientific publication reviewer

I have reviewed 11 publications (Web of Science Reviewer Profile) in the following journals:

1. Immunopharmacology and Immunotoxicology (3 εργασίες)
2. Frontiers in Oncology (3 εργασίες)
3. World Journal of Surgical Oncology (1 εργασία)
4. Frontiers in Immunology (1 εργασία)
5. BMC Gastroenterology (1 εργασία)
6. Lung Cancer: Targets and Therapy (1 εργασία)
7. Cancer Management and Research (1 εργασία)

Invited Talks

Presenter

1. "**After neoadjuvant therapy and surgery in resectable NSCLC**", Clinical and Translational Oncology Conference, Heraklion, November 2026
2. "**Systemic Therapies in Early-Stage RCC**", Interdisciplinary Education for the Treatment of Neoplastic Diseases, Chania, October 2026
3. "**Beyond EGFR and ALK in Early-Stage NSCLC**", 7th International Meeting on Lung Cancer, Athens, June 2026
4. "**Systemic anti-tumour immunity in clinical outcomes**", Molecular analysis for precision cancer therapy workshop, Heraklion, February 2026
5. "**Pathogenetic background of obesity and carcinogenesis**", Scientific Conference "The Unified Approach to Metabolic Diseases in the Era of Precision Medicine", Heraklion, January 2026
6. "**Reprogramming of immune cell metabolism and biomarkers of response to immunotherapy**", Clinical and Translational Oncology Conference, Heraklion, November 2025
7. "**Advances in immunotherapy of solid tumors and immune adverse reactions**", 17th EPEMY Panhellenic Conference, Rethymno, October 2025

8. "**Resectable NSCLC: Neoadjuvant, adjuvant ή perioperative; And with what;**", Oncology: Quo Vadis?, Athens, September 2025
9. "**Immunotherapies in Cancer**", 5th School of Immunology for Clinicians, Heraklion, May 2025
10. "**ctDNA – how far are we from its clinical application?**", 2nd Lung Cancer Clinical Seminar, Hellenic Lung Cancer Society, Pelion, May 2025
11. "**Tumor-agnostic targets and clinical targeting: NTRK inhibitors, BRAF V600E, HER2**", Molecular analysis for precision cancer therapy workshop, Heraklion, February 2025
12. "**Rare EGFR, HER2 mutations, Clinical efficacy of approved targeted agents: indications, efficacy and toxicity**", Molecular analysis for precision cancer therapy workshop, Heraklion, February 2024
13. "**Detection of KRAS mutations using ddPCR**", Molecular analysis for precision cancer therapy workshop, Ηράκλειο, February 2024
14. "**The sustained value of follow-up in lung cance**r", 14th Oncology Training Conference, Salonica, November 2022

Discussant

1. "**Challenges and Opportunities in Palliative Care**", Chania, October 2026
2. "**Tackling cancer pain**", Clinical and Translational Oncology Conference, Heraklion, November 2024
3. "**Balancing the Benefit and Toxicity of Treatment**", Clinical and Translational Oncology Conference, Heraklion, November 2023

Presentations in scientific conferences

Oral Presentations

1. Boukouris AE, Samara S, "Diagnosis of septic arthritis in a 78-year-old man with recent-onset hip pain", 12th year Forefronts in Internal Medicine, Athens, March 2023

2. Boukouris AE, Michelakis I, Tsoukalas M, et al. “Study of the correlation of vaccination coverage with duration of hospitalization and disease severity in hospitalized patients with SARS-CoV-2 infection”, 48th Annual Panhellenic Medical Congress, Athens, May 2022

Posters

1. Agelaki S, Chatziavraam S, Stylianou A, Koutoulaki C, Saridakis G, Lydaki D, Boukouris AE, Papadaki M, Mavroudis D. “Longitudinal assessment of circulating tumor cells (CTCs) in the peripheral blood of patients with metastatic breast cancer (MBC) on treatment with CDK4/6 inhibitors” ASCO 2026 Annual Meeting Abstract

2. Papadaki M, Zioudas C, Chatziavraam S, Boubouli A, Vorrias E, Boukouris AE, Kamaratou M, Papadakis M, Mavroudis D, Agelaki S, “Liquid biopsy analyses to highlight biomarkers of prognostic significance in patients with extensive-stage small cell lung cancer”, 9th Hellenic Oncology Congress, Salonica, April 2026

3. Agelaki S, Mortoglou M, Papadaki C, Boukouris AE, Michaelidou K et al., “A six-miRNA Signature Associated with Platinum Sensitivity and Tumor Immune Contexture in Non-Small Cell Lung Cancer Patients”, European Lung Cancer Congress (ELCC), Copenhagen, March 2026

4. Agelaki S, Michaelidou K, Vagiatis V, Koutoulaki C, Koutsopoulos AV, Boukouris AE et al., “Gene expression analysis of PD-1 and PD-L1 in peripheral blood mononuclear cells (PBMCs) in non-small cell lung cancer (NSCLC) patients: Association with KRAS mutation status and patient outcomes”, European Lung Cancer Congress (ELCC), Paris, March 2025

5. Michaelidou K, Boukouris AE, Koutoulaki C, Dimaras P, Mavroudis D, Agelaki S, “Development of a digital droplet PCR (ddPCR) methodology for the detection of mutations of clinical significance in the ESR1 gene in plasma samples from patients with hormone-sensitive HER2-negative, metastatic breast cancer”, 7th Hellenic Oncology Congress, Salonica, April 2024

6. Samara S, Boukouris AE, Mougakou E et al., “Interesting case of a patient with esophageal involvement and acquired hemophilia from bullous pemphigoid”, 49th Annual Panhellenic Medical Congress, Athens, May 2023

7. (ePoster) – Michelakis I, Dafni M, Komodromou A, Foteinou S, Boukouris A et al., "Omicron innocent until proven guilty?", 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, April 2023
8. Boukouris A, Michelakis I, Metaxas D, Karapati G, Kanellis G, Lioni A, Tzavara V, "The devil was in the mastocytes - A rare case of systemic mastocytosis (SM) in a 50-year-old male patient, missed for almost 20 years", 21st European Congress of Internal Medicine (ECIM), Athens, March 2023
9. (ePoster) – Michelakis I, Boukouris AE, Fetsis N, Doumouliaka E et al., " Study in COVID-19 patients (Omicron variant): Correlation of severity and disease outcome with vaccination and time from the last dose", 21st Panhellenic Congress of Infections, Athens, May 2022
10. Boukouris AE, Kirstein MM, Pothiraju D, Manns MP, Vogel A, "Low 4E-BP1 Expression sensitizes HCC Cells to the PI3K-Inhibitor BKM120", European Association for the Study of the Liver (EASL) Special Monothematic Conference – Systems Biology of the Liver, Luxembourg, February 2013

Participation in educational conferences

1. "**ETOP (European Thoracic Oncology Platform) Annual Meeting 2026**", Zurich
2. "**ETOP (European Thoracic Oncology Platform) Annual Meeting 2025**", Rome
3. "**2nd Masterclass in Lung Cancer (Managing early-stage NSCLC)**", Hellenic Lung Cancer Society, Pelion, May 2025
4. "**NET Masterclass – Clinical Perspectives on the Evolving Treatment Landscape of NETs**", Organized by IPSEN, Athens, December 2024
5. "**Best of ESMO 2024**" (Webinar), Hellenic Society of Medical Oncology, Athens, October 2024
6. "**Current challenges in cancer research: from bench to bedside**", Organized by the University of Crete, Heraklion, March 2024
7. "**7ο Educational Symposium – Melanoma, Skin cancers, Agreements & Disagreements**", Oncology Research and Education Society, Athens, December 2021

Membership in scientific societies

1. European Society of Medical Oncology (ESMO)
2. American Society of Clinical Oncology (ASCO)
3. International Association for the Study of Lung Cancer (IASLC)
4. European Thoracic Oncology Group (ETOP)
5. Hellenic Group of Young Oncologists (HeGYO)
6. European Cancer Organisation, Young Cancer Professionals (YCP)
7. Hellenic Sarcomas and Rare Tumors Group – Documentation of sarcoma cases in the respective database (registry) on behalf of Medical Oncology Clinic, University General Hospital of Heraklion

Certifications

ECFMG Certification (03/2020) – Successful completion of examinations to obtain a medical license in the US (USMLE Step 1, Step 2 CK, Step 2 CS)

FELASA B Certification (12/2013) – Successful completion of a seminar on the proper handling of experimental animal models in research protocols

Foreign Languages

English – Advanced (Cambridge Proficiency, CPE)
German – Advanced (Kleines Deutsches Sprachdiplom, KDS)

Voluntary Work

VP External, Department of Medicine Graduate Students' Association, University of Alberta, Edmonton, Canada, 03-09/2020